Alginate Oligosaccharides Ameliorate DSS-Induced Colitis through Modulation of AMPK/NF-κB Pathway and Intestinal Microbiota

• Published in: Nutrients Vol. 14; no. 14; p. 2864
• Main Authors: Zhang, Yue, Guo, Congcong, Li, Yanru, Han, Xianlei, Luo, Xuegang, Chen, Liehuan, Zhang, Tongcun, Wang, Nan, Wang, Weiming
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 13-07-2022; MDPI
• Subjects: alginate oligosaccharides; Alginates; Alginic acid; AMPK; Bone marrow; Cytokines; Dextran; Dextrans; Digestive system; IL-1β; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Interleukin 10; Interleukin 6; intestinal microbiota; Intestinal microflora; Kinases; Laboratory animals; Lipopolysaccharides; Macrophages; Microbiota; NF-κB; NF-κB protein; Nitric oxide; Oligosaccharides; Phosphorylation; Remission; rRNA 16S; Sodium sulfate; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Ulcerative colitis; Minneapolis Minnesota; Beijing China; United States > US; China
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu14142864

Alginate oligosaccharides (AOS) are shown to have various biological activities of great value to medicine, food, and agriculture. However, little information is available about their beneficial effects and mechanisms on ulcerative colitis. In this study, AOS with a polymerization degree between 2 and 4 were found to possess anti-inflammatory effects in vitro and in vivo. AOS could decrease the levels of nitric oxide (NO), IL-1β, IL-6, and TNFα, and upregulate the levels of IL-10 in both RAW 264.7 and bone-marrow-derived macrophage (BMDM) cells under lipopolysaccharide (LPS) stimulation. Additionally, oral AOS administration could significantly prevent bodyweight loss, colonic shortening, and rectal bleeding in dextran sodium sulfate (DSS)-induced colitis mice. AOS pretreatment could also reduce disease activity index scores and histopathologic scores and downregulate proinflammatory cytokine levels. Importantly, AOS administration could reverse DSS-induced AMPK deactivation and NF-κB activation in colonic tissues, as evidenced by enhanced AMPK phosphorylation and p65 phosphorylation inhibition. AOS could also upregulate AMPK phosphorylation and inhibit NF-κB activation in vitro. Moreover, 16S rRNA gene sequencing of gut microbiota indicated that supplemental doses of AOS could affect overall gut microbiota structure to a varying extent and specifically change the abundance of some bacteria. Medium-dose AOS could be superior to low- or high-dose AOS in maintaining remission in DSS-induced colitis mice. In conclusion, AOS can play a protective role in colitis through modulation of gut microbiota and the AMPK/NF-kB pathway.